⌕
Waters · WAT · NYSE
Tenet 34 · Weak
Compare
$449.78−0.80%At closeTenet 34 · Weak
$449.78−3.64 (−0.80%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$449.00−0.78 (−0.17%)
After hours: Nov 17, 2026, 4:30 PM ET

Waters (WAT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is WAT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 17, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference

MILFORD, Mass., Nov. 17, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.…

WAT −0.8% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 07:48 ETEARNINGS EXPECTED BY FEB 8
International Seaways: Even After Some Rough Waters, INSW Is Still A Buy

I rate International Seaways a Buy: my $123.56 dividend-discount valuation implies 17.4% upside from $105.23. INSW's spot exposure captures elevated tanker rates amid persistent regional shipping risks; reserve replenish…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 13:11 ET
Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers

WAT gains FDA clearance for two blood cancer diagnostic tests, advancing standardized testing and expanding its clinical diagnostics portfolio.…

WAT −0.8% todayRead at source ↗
● PRNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma

BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying chronic lymphocytic leukem…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 12:55 ET
Waters Expands Proteomics Reach With MOBILion Systems Acquisition

WAT expands its proteomics footprint with the MOBILion acquisition, boosting mass spectrometry capabilities, AI-driven research and clinical testing prospects.…

WAT −0.8% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 01:30 ETEARNINGS EXPECTED BY FEB 8
Madison Mid Cap Fund Q3 2026 Portfolio Activity

The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvi…

WAT −0.8% todayRead at source ↗
● MarketBeatNov 4, 2026 · 06:14 ETEARNINGS EXPECTED BY FEB 8
Waters Q3 Earnings Call Highlights

Waters NYSE: WAT reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, as the company cited double-digit organic growth, improving performance in acquired businesses and cost act…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 14:11 ETEARNINGS EXPECTED BY FEB 8
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised

WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.…

WAT −0.8% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 11:45 ETEARNINGS EXPECTED BY FEB 8
Waters Corporation (WAT) Q3 2026 Earnings Call Transcript

Waters Corporation (WAT) Q3 2026 Earnings Call Transcript…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 8
Waters (WAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Waters (WAT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 08:11 ETEARNINGS EXPECTED BY FEB 8
Waters (WAT) Beats Q3 Earnings and Revenue Estimates

Waters (WAT) came out with quarterly earnings of $4.1 per share, beating the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $3.4 per share a year ago.…

WAT −0.8% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 06:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results

Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by organic revenue growt…

WAT −0.8% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 05:55 ETCOMPANY'S OWN WORDS
Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery

Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry platform, transform…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 14:56 ETEARNINGS EXPECTED BY FEB 8
Waters Gears Up to Report Q3 Results: How to Play the Stock?

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.…

WAT −0.8% todayRead at source ↗
● PRNewsWireOct 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software

Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over 80% of medicines glo…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 13:36 ET
Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests

WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.…

WAT −0.8% todayRead at source ↗
● PRNewsWireOct 23, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, …

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:20 ET
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows

WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.…

WAT −0.8% todayRead at source ↗
● PRNewsWireOct 20, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test th…

WAT −0.8% todayRead at source ↗
● InvezzOct 19, 2026 · 14:22 ET
Two stocks poised to benefit from rotation out of AI

Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the Ritholtz' chief execu…

WAT −0.8% todayRead at source ↗
● PRNewsWireOct 13, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' uniq…

WAT −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 8, 2026 · 11:10 ET
Here's Why You Should Retain WAT Stock in Your Portfolio for Now

Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.…

WAT −0.8% todayRead at source ↗
● Defense WorldOct 6, 2026 · 11:01 ET
Waters (NYSE:WAT) Reaches New 52-Week High – Time to Buy?

Shares of Waters Corporation (NYSE: WAT - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $454.54 and last traded at $444.9030, with a volume of 52745 shares changing hands.…

WAT −0.8% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call

MILFORD, Mass., Oct. 1, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q3 2026 financial results conference call on Tuesday, November 3, 2026, at 8:00 a.m.…

WAT −0.8% todayRead at source ↗
● Business WireSep 16, 2026 · 10:00 ET
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients

AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening…

WAT −0.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just WAT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.